Key points from article :
NeuroSense partners with Lonza to identify biomarkers for early diagnosis & improve treatment for neurodegenerative diseases.
NeuroSense raised $4.5 million to support ongoing research and development.
Lonza's expertise will be used to develop methods using neuron-derived exosomes.
NeuroSense's lead drug PrimeC shows promise in treating ALS.
PrimeC aims to slow disease progression and is preparing for a Phase 2b/3 clinical trial in ALS.
NeuroSense is also developing treatments for Alzheimer’s and Parkinson’s based on PrimeC.
